NCT06094036

Brief Summary

Aim of this project is to delineate sustainable physical exercise programs and to assess the effects of such programs mainly on endocrine-metabolic and neurovegetative outcomes in a cohort of men with metabolic syndrome-related late-onset central hypogonadism. Participants will undergo a personalised exercise program. After 6 months they will be subdivided into two groups, according to the weekly physical activity volume actually performed (above or below 600 MET·minutes/week). Changes in endocrine-metabolic and neurovegetative outcomes will be compared between the two groups.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

October 6, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

October 23, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

March 12, 2024

Status Verified

March 1, 2024

Enrollment Period

1.9 years

First QC Date

October 6, 2023

Last Update Submit

March 8, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in hypothalamic-pituitary-gonadal axis function

    particularly testosterone levels (nmol/l)

    6 months

Secondary Outcomes (16)

  • Change in body composition

    6 months

  • Change in serum skeletal isoenzyme of alkaline phosphatase

    6 months

  • Change in C-terminal telopeptide of type I collagen

    6 months

  • Change in erythrocyte sedimentation rate

    6 months

  • Change in C-reactive protein

    6 months

  • +11 more secondary outcomes

Study Arms (2)

weekly physical activity volume performed above 600 MET·minutes/week

OTHER

Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.

Behavioral: Structured and personalized program of physical exercise

weekly physical activity volume performed below 600 MET·minutes/week

OTHER

Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.

Behavioral: Structured and personalized program of physical exercise

Interventions

In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals. This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality.

weekly physical activity volume performed above 600 MET·minutes/weekweekly physical activity volume performed below 600 MET·minutes/week

Eligibility Criteria

Age18 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of late-onset central hypogonadism: total T levels \< 8 nmol/L (or \< 12 nmol/L in the presence of calculated free T \< 225 pmol/L) combined with sexual symptoms (erectile dysfunction, low libido and loss of waking erections) \[12\];
  • diagnosis of metabolic syndrome, defined as association of waist circumference (WC) \> 94 cm and at least two among the following criteria: triglycerides ≥ 150 mg/dl, HDL-C \< 40 mg/dl, glucose \> 100 mg/dl, blood pressure (BP) ≥ 130/85 mmHg \[33\];
  • ability to give informed consent, in accordance with good clinical practice rules and applicable national laws.

You may not qualify if:

  • History of hypothalamus-pituitary organic disorders and/or testicular diseases;
  • impossibility to assess cardiac autonomic regulation due to arrhythmias and/or current treatment for heart rate (HR) control (e.g., beta-blockers, antiarrhythmics);
  • impossibility to undergo clinical assessment;
  • impossibility or contraindications to perform exercise program (for instance, psychiatric disorders, severe musculoskeletal diseases, arrhythmias);
  • inability to give informed consent or unwillingness to be enrolled in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituto Auxologico Italiano IRCCS

Milan, Italy

RECRUITING

MeSH Terms

Conditions

EunuchismMetabolic SyndromeSedentary Behavior

Condition Hierarchy (Ancestors)

HypogonadismGonadal DisordersEndocrine System DiseasesInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesBehavior

Study Officials

  • Daniela Lucini, MD, PhD

    University of Milan; Istituto Auxologico Italiano, IRCCS

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Luca Giovanelli, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 6, 2023

First Posted

October 23, 2023

Study Start

January 11, 2023

Primary Completion

December 1, 2024

Study Completion

December 31, 2024

Last Updated

March 12, 2024

Record last verified: 2024-03

Locations